Cardiology

Laurence Sperling, MD, and Eugenia Gianos, MD, discuss the historical context and underutilization of lipoprotein apheresis in part 1 of a 3-part video series.

Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.

The sNDA submission to the FDA included a Priority Review Voucher, which commits the regulatory agency to an accelerated review timeline.

Linda Gillam, MD, MPH, discusses the idea that the cardiology community may. be overtreating aortic stenosis.

Optimal use of GDMT therapy in heart failure could save an estimated 1.19 million lives globally over the course of 1 year.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

Taher Modarressi, MD, sits down with hosts to share tips and practical nuggets for cardiometabolic health specialists to optimize prescription and adherence to newer therapies.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

Steve Nissen, MD, discusses how the cardiology community needs to learn from previous mistakes in uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents.

Subclinical atherosclerosis burden and its progression are independently linked to the risk of death from any cause in asymptomatic individuals.

Family Heart Foundation announces the launch of Cholesterol Connect, a program that provides free at-home lipid screening and personalized support.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

HCPLive spoke to Rodriguez, MD, MPH, about implementing AI in cardiology care.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

At the Family Heart Global Summit 2024, Bhatia spoke about the importance of universal Lp(a) screening over only targeted screening.

In this episode, John Giacona, PhD, PA-C, shares insights from the 2024 AHA Hypertension Scientific Sessions, focusing on primary aldosteronism and renal denervation.

In an interview O’Donoghue talked about emerging RNA therapies for Lp(a) in phase 2 and 3 trials.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

A randomized trial suggests gefarnate significantly reduces triglycerides and LDL-C in older adults on statins with residual hypertriglyceridemia.

The joint guidelines address evidence on the management of patients before, during, and after noncardiac surgery since the last update in 2014.